XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
May 01, 2023
Apr. 04, 2023
Apr. 03, 2023
Apr. 03, 2023
Mar. 31, 2023
Mar. 29, 2023
Feb. 05, 2020
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Aug. 31, 2022
Feb. 14, 2020
Class of Stock [Line Items]                        
Cash and cash equivalents         $ 83,391     $ 83,391   $ 73,981    
Marketable securities         $ 17,532     $ 17,532   $ 22,518    
Quarterly net revenue target for royalty financing           $ 25,000            
Ordinary shares, nominal value (in usd per share)         $ 0.01     $ 0.01   $ 0.01    
Proceeds from issuance of shares off the at-the-market offering program               $ 11,913 $ 0      
Issuance of common stock under at-the-market offering program, net of issuance costs               $ 11,913        
Ordinary shares                        
Class of Stock [Line Items]                        
February 2020 private placement (in shares)               1,564        
Issuance of common stock under at-the-market offering program, net of issuance costs               $ 16        
Forecast                        
Class of Stock [Line Items]                        
Royalty financing $ 30,000                      
Subsequent Event                        
Class of Stock [Line Items]                        
Term of orphan drug exclusivity 7 years                      
Public Stock Offering | Subsequent Event                        
Class of Stock [Line Items]                        
Proceeds from issuance of shares off the at-the-market offering program     $ 135,125 $ 135,125                
Public Stock Offering, Tranche One                        
Class of Stock [Line Items]                        
Proceeds from stock offering         $ 40,000              
Public Stock Offering, Tranche Two | Subsequent Event                        
Class of Stock [Line Items]                        
Proceeds from stock offering       95,125                
2020 Shelf Registration Statement                        
Class of Stock [Line Items]                        
Sales agent commission, as a percent of aggregate gross sales proceeds             3.00%          
Maximum aggregate offering price of ADSs under shelf registration                       $ 50,000
2022 Shelf Registration Statement                        
Class of Stock [Line Items]                        
Maximum aggregate offering price of ADSs under shelf registration                     $ 100,000  
At-The-Market Offering Program                        
Class of Stock [Line Items]                        
Remaining authorized aggregate offering price under shelf registration         $ 96,064     $ 96,064        
Maximum                        
Class of Stock [Line Items]                        
Royalty financing           $ 75,000            
4.50% Exchangeable Senior Notes Due October 2023                        
Class of Stock [Line Items]                        
Interest rate         4.50%     4.50%        
4.50% Exchangeable Senior Notes Due October 2023 | Senior Notes                        
Class of Stock [Line Items]                        
Long-term debt         $ 117,375     $ 117,375   $ 117,375    
Interest rate         4.50%     4.50%        
4.50% Exchangeable Senior Notes Due October 2023 | Senior Notes | Subsequent Event                        
Class of Stock [Line Items]                        
Long-term debt   $ 21,187                    
Debt exchanged   $ 96,188   96,188                
April 2027 Notes | Subsequent Event                        
Class of Stock [Line Items]                        
Interest rate   6.00%                    
April 2027 Notes | Senior Notes | Subsequent Event                        
Class of Stock [Line Items]                        
Long-term debt   $ 106,268 $ 106,268 $ 106,268